

Lidia Usnarska-Zubkiewicz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5216437/publications.pdf>

Version: 2024-02-01

50
papers

442
citations

840119

11
h-index

839053

18
g-index

53
all docs

53
docs citations

53
times ranked

925
citing authors

#	ARTICLE	IF	CITATIONS
1	Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors. <i>American Journal of Hematology</i> , 2022, 97, 877-884.	2.0	12
2	Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis. <i>Haematologica</i> , 2021, 106, 601-604.	1.7	2
3	Differential Function of a Novel Population of the CD19+CD24hiCD38hi Bregs in Psoriasis and Multiple Myeloma. <i>Cells</i> , 2021, 10, 411.	1.8	7
4	Platelet Reactivity and Response to Aspirin and Clopidogrel in Patients with Platelet Count Disorders. <i>Cardiology Research and Practice</i> , 2021, 2021, 1-7.	0.5	1
5	Risk factors and causes for early mortality in patients with newly diagnosed multiple myeloma in a "real world" study: experiences of the Polish Myeloma Group. <i>Polish Archives of Internal Medicine</i> , 2021, 131, 527-534.	0.3	4
6	An asymptomatic course of SARS-CoV-2 infection in a patient with three different neoplasms and treated with bortezomib – a coincidence or new therapeutic possibility. <i>Polish Archives of Internal Medicine</i> , 2021, 131, 747-748.	0.3	0
7	Deregulated Expression of Immune Checkpoints on Circulating CD4 T Cells May Complicate Clinical Outcome and Response to Treatment with Checkpoint Inhibitors in Multiple Myeloma Patients. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9298.	1.8	8
8	Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group. <i>Journal of Clinical Medicine</i> , 2021, 10, 5504.	1.0	1
9	Primary refractory multiple myeloma: a real-world experience with 85 cases. <i>Leukemia and Lymphoma</i> , 2020, 61, 2868-2875.	0.6	6
10	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, 503-509.	2.0	11
11	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1885-1893.	0.6	3
12	Platelet polyphosphate level is elevated in patients with chronic primary thrombocytopenia: A preliminary study. <i>Advances in Clinical and Experimental Medicine</i> , 2020, 29, 1051-1056.	0.6	4
13	Autologous stem cell transplantation in the treatment of multiple myeloma patients with 17p deletion. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 106-111.	0.3	1
14	Early Mortality in Patients with Multiple Myeloma Treated with Novel Agents - Analysis from Polish Myeloma Study Group. <i>Blood</i> , 2020, 136, 36-37.	0.6	0
15	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 118-123.	0.6	23
16	Hematogenous extramedullary relapse in multiple myeloma – a multicenter retrospective study in 127 patients. <i>American Journal of Hematology</i> , 2019, 94, 1132-1140.	2.0	24
17	Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma. <i>Advances in Medical Sciences</i> , 2019, 64, 349-355.	0.9	16
18	High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group. <i>Oncology Letters</i> , 2019, 18, 5811-5820.	0.8	4

#	ARTICLE	IF	CITATIONS
19	The analysis of the parameters of 24-hour ECG Holter monitoring in patients with blood neoplasms undergoing high-dose chemotherapy and stem cell transplantation. <i>Annals of Noninvasive Electrocardiology</i> , 2018, 23, e12534.	0.5	6
20	Quality of life assessment in multiple myeloma patients – preliminary report. <i>Palliative Medicine</i> , 2018, 10, 208-215.	0.1	0
21	Evaluation of the impact of treatment with hematopoietic stem cells transplantation (HSCT) on biochemical markers of heart function and novel electrocardiographic markers of repolarization in patients with hematological malignancies. <i>Medical Oncology</i> , 2018, 35, 162.	1.2	1
22	The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?. <i>Blood</i> , 2018, 132, 4452-4452.	0.6	3
23	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytoowych na rok 2018/2019. <i>Acta Haematologica Polonica</i> , 2018, 49, 157-206.	0.1	4
24	Ascites in the Course of Plasma Cell Myeloma Complicated by AL Amyloidosis. <i>Turkish Journal of Haematology</i> , 2018, 35, 71-72.	0.2	0
25	Hematogenous Extramedullary Relapse in Multiple Myeloma - A Multicenter Retrospective Study in 127 Patients. <i>Blood</i> , 2018, 132, 2004-2004.	0.6	1
26	Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group. <i>Leukemia and Lymphoma</i> , 2017, 58, 2089-2100.	0.6	12
27	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytoowych na rok 2017. <i>Acta Haematologica Polonica</i> , 2017, 48, 55-103.	0.1	5
28	Real-life experience with bortezomib-based regimens in elderly comorbid patients with newly diagnosed multiple myeloma – Polish retrospective multicenter analysis. <i>Polish Archives of Internal Medicine</i> , 2017, 127, 765-774.	0.3	7
29	Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy. <i>Oncotarget</i> , 2016, 7, 56726-56736.	0.8	58
30	Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. <i>American Journal of Hematology</i> , 2016, 91, 575-580.	2.0	83
31	Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study. <i>British Journal of Haematology</i> , 2016, 175, 884-891.	1.2	21
32	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytoowych na rok 2016. <i>Acta Haematologica Polonica</i> , 2016, 47, 39-85.	0.1	10
33	Echocardiographic evaluation of the early cardiotoxic effect of hematopoietic stem cell transplantation in patients with hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2016, 57, 2119-2125.	0.6	3
34	Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients – Report of the Polish Myeloma Group. <i>Leukemia Research</i> , 2016, 40, 90-99.	0.4	3
35	Endothelial Function in Patients with Hematologic Malignancies Undergoing High-Dose Chemotherapy Followed by Hematopoietic Stem Cell Transplantation. <i>Cardiovascular Toxicology</i> , 2016, 16, 156-162.	1.1	10
36	Abnormal Distribution of Gamma-Delta T Lymphocytes and Their Subsets in Type 1 Diabetes. <i>Advances in Clinical and Experimental Medicine</i> , 2016, 25, 665-671.	0.6	10

#	ARTICLE	IF	CITATIONS
37	Altered Endothelial Cells Properties and Platelets Activity in Treatment Na ⁺ -Ve Patients with Multiple Myeloma (MM) and Non-Hodgkin Lymphoma (nHL): Association with Thromboembolic Complications. <i>Blood</i> , 2016, 128, 5649-5649.	0.6	0
38	Dziesi [™] ciolecie Polskiej Grupy Szpiczakowej â€“ historia i osi [™] gni [™] cia. <i>Acta Haematologica Polonica</i> , 2015, 46, 212-223.	0.1	0
39	Heart Rate Variability and Heart Rate Turbulence in Patients with Hematologic Malignancies Subjected to Highâ€šDose Chemotherapy in the Course of Hematopoietic Stem Cell Transplantation. <i>Annals of Noninvasive Electrocardiology</i> , 2014, 19, 157-165.	0.5	16
40	Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effectiveâ€”A report by Polish Myeloma Study Group. <i>Leukemia Research</i> , 2014, 38, 788-794.	0.4	4
41	Analysis of Free Serum Light Chains in Patients Suffering from Multiple Myeloma Complicated by Light-Chain Amyloidosis. <i>Advances in Clinical and Experimental Medicine</i> , 2014, 23, 531-538.	0.6	3
42	Soluble Urokinase-Type Plasminogen Activator Receptor and Ferritin Concentration in Patients with Advanced Alimentary Tract Carcinoma. Relationship to Localization, Surgical Treatment and the Stage of the Disease â€“ Preliminary Report. <i>Advances in Clinical and Experimental Medicine</i> , 2014, 23, 959-967.	0.6	10
43	The Occurrence of AL Amyloidosis (Light-Chain Amyloidosis) in Patients with Multiple Myeloma in Lower Silesia Region, Poland. <i>Advances in Clinical and Experimental Medicine</i> , 2014, 23, 235-244.	0.6	2
44	Impact of Anthracycline-Based Induction Chemotherapy on the Calreticulin, CD47 Exposure and the Percentage of Regulatory T Cells in Patients with Acute Leukemias: Preliminary Study. <i>Blood</i> , 2014, 124, 5259-5259.	0.6	0
45	Review Bortezomib-induced painful neuropathy in patients with multiple myeloma. <i>Wspolczesna Onkologia</i> , 2013, 5, 421-426.	0.7	12
46	Zalecenia Polskiej Grupy Szpiczakowej dotycz [™] ce rozpoznawania i leczenia szpiczaka plazmocytoowego na rok 2012. <i>Acta Haematologica Polonica</i> , 2012, 43, 7-47.	0.1	5
47	Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma (MM) Patients: a Preliminary Report of Polish Myeloma Group. <i>Blood</i> , 2011, 118, 5125-5125.	0.6	0
48	The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 307 Td Group. <i>Leukemia Research</i> , 2010, 34, 1330-1335.	0.4	14
49	Pregnancy in a woman with polycystic ovary syndrome and myelodysplastic syndrome (in the form of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 307 Td Group. <i>Gynecological Endocrinology</i> , 2010, 26, 135-138.	0.7	1
50	Molecular Characterization of Mouse Monoclonal Antibody BIII. 136 and the Epitope Recognized by the Antibody in Human Band 3 Protein. <i>Hybridoma</i> , 1995, 14, 217-223.	0.9	4